Back to results
US 2006/0135576 A1Published application
Heterocyclic inhibitors of kinases
AssigneeBristol-Myers Squibb Company
InventorsRobert Borzilleri, Rajeev Bhide, John Tokarski, Peter Zheng, Ligang Qian, Zhen-Wei Cai
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Claims17
A compound of formula I
- wherein
- A and B are independently selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclo, substituted heterocyclo, lower alkyl, arylalkyl, alkylaryl and alkylheteroaryl;
- X is selected from the group consisting of R1CR2, S, O, SO2, SO and NR3, with the proviso that at least one of X and Y is R1CR2;
- Y is selected from the group consisting of R1CR2, S, SO2, SO and NR3, with the proviso that at least one of X and Y is R1CR2;
- D is selected from the group consisting of S, O, and NR4;
- R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, substituted heterocycle, aralkyl, arylalkyl, substituted aralkyl, COR5 and SO2R6;
- R5 and R6 are independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heterocycloalkyl and substituted heterocycloalkyl;
- and
- its enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof.
6 more elements
A compound of the formula
- wherein
- B is a pyridinyl group optionally substituted with 1-4 substituents;
- A is substituted aryl.
- X is selected from the group consisting of R1CR2, S, O, SO2, SO and NR3;
- Y is selected from the group consisting of R1CR2, S, SO2, SO and NR3, with the proviso that at least one of X and Y is R1CR2;
- with the proviso that at least one of X and Y is R1CR2;
- and its enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof.
4 more elements
A compound selected from the group consisting of
- 2,4-Difluoro-N-methyl-5-{[2-(Pyridin-2-ylamino)-thiazole-5-ylmethyl]-amino}-benzamide;
- 4-Fluoro-N-methyl-3-{[2-(pyridin-2-ylamino)-thiazol-5-ylmethyl]-amino }-benzamide;
- N-Cyclopropyl-4-fluoro-3-{[2-(pyridin-2-ylamino)-thiazol-5-ylmethyl]-amino}-benzamide;
- N-Cyclopropyl-4-fluoro-3-{2-[2-(pyridin-2-ylamino)-thiazol-5-yl]-ethyl}-benzamide;
- N-Cyclopropyl-2,4-difluoro-5-{[2-(4-methyl-pyridin-2-ylamino)-thiazol-5-ylmethyl]-amino}-benzamide;
- N-Cyclopropyl-2,4-difluoro-5-{[2-(pyridin-2-ylamino)-thiazol-5-ylmethyl]-amino}-benzamide
- N-Cyclopropyl-2,4-difluoro-5-({2-[5-(4-methyl-piperazine-1-carbonyl)-pyridin-2-ylamino]-thiazol-5-ylmethyl}-amino)-benzamide;
- 6-{5-[(5-Cyclopropylcarbamoyl-2,4-difluoro-phenylamino)-methyl]-thiazol-2-ylamino}-N-(2-dimethylamino-ethyl)-N-methylnicotinamide;
- 6-{5-[2-(5-Cyclopropylcarbamoyl-2-fluoro-phenyl)-ethyl]-thiazol-2-ylamino}-N-(2-ethylamino-ethyl)-nicotinamide;
- 4-Fluoro-3-{[2-(pyridin-2-ylamino)-thiazol-5-ylmethyl]-amino}-N-thiophen-2-ylmethylbenzamide;
- N-Benzyl-4-fluoro-3-{[2-(pyridin-2-ylamino)-thiazol-5-ylmethyl]-amino}-benzamide;
- 4-Fluoro-3-{[2-(pyridin-2-ylamino)-thiazol-5-ylmethyl]-amino}-N-pyridin-2-ylmethylbenzamide;
- 4-Fluoro-N-(3-morpholin-4-yl-propyl)-3-{[2-(pyridin-2-ylamino)-thiazol-5-ylmethyl]-amino}-benzamide;
- 4-Fluoro-N-prop-2-ynyl-3-{[2-(pyridin-2-ylamino)-thiazol-5-ylmethyl]-amino}-benzamide;
- 4-Fluoro-N-isoxazol-3-yl-3-{[2-(pyridin-2-ylamino)-thiazol-5-ylmethyl]-amino}-benzamide
- 4-Fluoro-N-(5-methyl-isoxazol-3-yl)-3-{[2-(pyridin-2-ylamino)-thiazol-5-ylmethyl]-amino}-benzamide;
- and
- N-(2,2-Difluoro-3-morpholin-4-yl-propyl)-4-fluoro-3-{[2-(pyridin-2-ylamino)-thiazol-5-ylmethyl]-amino}-benzamide.
15 more elements
Dependencies are inferred from the claim text.